THIS WEEK'S FEATURE
Sweden’s Moberg Pharma (OMX:MOB) is focused on maximizing the potential of its market leading position in over-the-counter sales of topical dermatology products to drive development of new therapies for the treatment of nail fungus and mouth pain, especially in cancer patients.
Closely-held Tear Film Innovations plans to formally launch at two upcoming medical conferences its iLux medical device to treat Meibomian gland dysfunction, the leading cause of dry eye disease.
Myomo (NYSE American:MYO) is moving from a controlled introduction over the past few years to a scale up sales and distribution of its MyoPro product line of lightweight, non-invasive, powered arm braces to restore function in paralyzed or weakened arms.
Australia is riding a wave of R&D, thanks to generous government tax incentives, as well as the quality of contract research and speed of performing clinical trials.
Vital Therapies (NASDAQ:VTL) expects to report top line data from its ELAD pivotal study, known as VTL-308, in patients with severe alcoholic hepatitis (sAH), an acute form of liver failure, by the end of the third quarter of 2018.